In the latest quarter, 4 analysts provided ratings for Anika Therapeutics (NASDAQ:ANIK), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
2
0
0
Last 30D
0
0
1
0
0
1M Ago
0
1
0
0
0
2M Ago
0
0
0
0
0
3M Ago
0
1
1
0
0
In the assessment of 12-month price targets, analysts unveil insights for Anika Therapeutics, presenting an average target of $30.0, a high estimate of $37.00, and a low estimate of $22.00. Consistency is reflected as the current average remains at the same level as the previous average price target.
Investigating Analyst Ratings: An Elaborate Study
The standing of Anika Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
George Sellers
Stephens & Co.
Maintains
Equal-Weight
$24.00
$24.00
Michael Petusky
Barrington Research
Maintains
Outperform
$37.00
$37.00
Michael Petusky
Barrington Research
Raises
Outperform
$37.00
$29.00
George Sellers
Stephens & Co.
Maintains
Equal-Weight
$22.00
-
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Anika Therapeutics. ...Full story available on Benzinga.com
Benzinga
Annovis Bio, Inc.